011000 — Gene One Life Science Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapSucker Stock

Annual cashflow statement for Gene One Life Science, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-7,619	-18,648	-15,951	-38,150	-77,768
Depreciation
Amortisation
Deferred Taxes
Non-Cash Items	3,192	849	-2,119	2,170	34,347
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-249	-2,169	8,306	6,153	8,901
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Taxes Payable
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-1,270	-15,916	-4,849	-24,113	-21,744
Capital Expenditures	-3,010	-16,370	-82,518	-45,408	-5,653
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	13,480	-27,935	-63,880	53,463	31,545
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	10,471	-44,305	-146,398	8,055	25,892
Financing Cash Flow Items	—	—	-850	-2.97	-5.64
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-657	106,235	111,023	7,013	-8,285
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	8,543	45,510	-40,122	-9,049	-4,150